The immune system in cancer prevention, development and therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 1, 2016, Pages 101-107

  Candéias, Serge M ^a   Gaipl, Udo S ^b  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Immune system; Immunotherapy; Inflammation; Tumor prevention; Tumor promotion

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CONCEPTUAL FRAMEWORK; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASMS;

CYTOKINE;

ANIMALS; CYTOKINES; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 84947941076     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150824153523     Document Type: Review

References (88)

1. Gordon, S.; Taylor, P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunology, 2005, 5(12), 953-964
2. Merad, M.; Sathe, P.; Helft, J.; Miller, J.; Mortha, A. The dendritic cell lineage: Ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Ann. Rev. Immunol., 2013, 31, 563-604.
3. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol., 2010, 11(5), 373-384.
4. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418(6894), 191-195.
5. Wallin, R.P.; Lundqvist, A.; More, S.H.; von Bonin, A.; Kiessling, R.; Ljunggren, H.G. Heat-shock proteins as activators of the innate immune system. Trends Immunol., 2002, 23(3), 130-135.
6. Bernard, J.J.; Cowing-Zitron, C.; Nakatsuji, T.; Muehleisen, B.; Muto, J.; Borkowski, A.W.; Martinez, L.; Greidinger, E.L.; Yu, B. D.; Gallo, R.L. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med., 2012, 18(8), 1286-1290.
7. Rock, K.L.; Latz, E.; Ontiveros, F.; Kono, H. The sterile inflammatory response. Ann. Rev. Immunol., 2010, 28, 321-342
8. Chen, G.Y.; Nunez, G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol., 2010, 10 (12), 826-837.
9. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol., 2002, 3(11), 991-998
10. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Ann. Rev. Immunol., 2004, 22, 329-360.
11. Trinchieri, G.; Perussia, B. Immune interferon: A pleiotropic lymphokine with multiple effects. Immunol. Today, 1985, 6(4), 131-136.
12. Farrar, M.A.; Schreiber, R.D. The molecular cell biology of interferon-gamma and its receptor. Ann. Rev. Immunol., 1993, 11, 571-611.
13. Ding, A.H.; Nathan, C.F.; Stuehr, D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol., 1988, 141(7), 2407-2412.
14. Dighe, A.S.; Richards, E.; Old, L.J.; Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity, 1994, 1(6), 447-456.
15. Kaplan, D.H.; Shankaran, V.; Dighe, A.S.; Stockert, E.; Aguet, M.; Old, L.J.; Schreiber, R.D. Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc. Nat. Acad. Sci.USA, 1998, 95(13), 7556-7561.
16. Donehower, L.A.; Harvey, M.; Slagle, B.L.; McArthur, M.J.; Montgomery, C.A.Jr.; Butel, J.S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 1992, 356(6366), 215-221
17. Jacks, T.; Remington, L.; Williams, B.O.; Schmitt, E.M.; Halachmi, S.; Bronson, R.T.; Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 1994, 4(1), 1-7.
18. Shinkai, Y.; Rathbun, G.; Lam, K.P.; Oltz, E.M.; Stewart, V.; Mendelsohn, M.; Charron, J.; Datta, M.; Young, F.; Stall, A.M. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell, 1992, 68(5), 855-867.
19. Diamond, R.A.; Ward, S.B.; Owada-Makabe, K.; Wang, H.; Rothenberg, E.V. Different developmental arrest points in RAG-2-/-and SCID thymocytes on two genetic backgrounds: Developmental choices and cell death mechanisms before TCR gene rearrangement. J. Immunol., 1997, 158(9), 4052-4064.
20. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P. E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410(6832), 1107-1111.
21. Kawasaki, A.; Shinkai, Y.; Yagita, H.; Okumura, K., Expression of perforin in murine natural killer cells and cytotoxic T lymphocytes in vivo. Euro. J. Immunol., 1992, 22(5), 1215-1219.
22. Van den Broek, M.E.; Kagi, D.; Ossendorp, F.; Toes, R.; Vamvakas, S.; Lutz, W.K.; Melief, C.J.; Zinkernagel, R.M.; Hengartner, H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med., 1996, 184(5), 1781-1790.
23. Smyth, M.J.; Thia, K.Y.; Street, S.E.; Cretney, E.; Trapani, J.A.; Taniguchi, M.; Kawano, T.; Pelikan, S.B.; Crowe, N.Y.; Godfrey, D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med., 2000, 191(4), 661-668.
24. Smyth, M.J.; Thia, K.Y.; Street, S.E.; MacGregor, D.; Godfrey, D. I.; Trapani, J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med., 2000, 192 (5), 755-760.
25. Street, S.E.; Cretney, E.; Smyth, M.J. Perforin and interferongamma activities independently control tumor initiation, growth, and metastasis. Blood, 2001, 97 (1), 192-197.
26. Street, S.E.; Trapani, J.A.; MacGregor, D.; Smyth, M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med., 2002, 196(1), 129-134.
27. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140(6), 883-899
28. Nathan, C.; Ding, A. Nonresolving inflammation. Cell, 2010, 140(6), 871-882.
29. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
30. Ostrand-Rosenberg, S.; Sinha, P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol., 2009, 182(8), 4499-4506
31. Solito, S.; Marigo, I.; Pinton, L.; Damuzzo, V.; Mandruzzato, S.; Bronte, V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N.Y. Acad.Sci., 2014, 1319, 47-65.
32. Bronte, V.; Serafini, P.; Mazzoni, A.; Segal, D.M.; Zanovello, P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trend. Immunol., 2003, 24(6), 302-306
33. Rodriguez, P. C.; Ochoa, A.C. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Sem. Cancer Biol., 2006, 16(1), 66-72
34. Srivastava, M. K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res., 2010, 70(1), 68-77
35. Rodriguez, P.C.; Quiceno, D.G.; Ochoa, A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 2007, 109 (4), 1568-1573.
36. Mellor, A.L.; Keskin, D.B.; Johnson, T.; Chandler, P.; Munn, D.H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol., 2002, 168(8), 3771-3776
37. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A. L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 1999, 189(9), 1363-1372
38. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med., 2003, 9(10), 1269-1274.
39. Muller, A.J.; DuHadaway, J.B.; Chang, M.Y.; Ramalingam, A.; Sutanto-Ward, E.; Boulden, J.; Soler, A.P.; Mandik-Nayak, L.; Gilmour, S.K.; Prendergast, G.C. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol., Immunother., 2010, 59(11), 1655-1663.
40. Shields, J.D.; Kourtis, I.C.; Tomei, A.A.; Roberts, J.M.; Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science, 2010, 328(5979), 749-752.
41. Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17(7), 2105-2116.
42. Weber, J.S. Immuno-oncology Comes of Age-Introduction. Sem. Oncol., 2014, 41(5), S1-S2.
43. Gaipl, U.S.; Multhoff, G.; Scheithauer, H.; Lauber, K.; Hehlgans, S.; Frey, B.; Rodel, F. Kill and spread the word: Stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy, 2014, 6(5), 597-610.
44. Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr. Opin. Immunol., 2014, 27, 16-25.
45. Galon, J.; Angell, H.K.; Bedognetti, D.; Marincola, F.M. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity, 2013, 39(1), 11-26.
46. Fridman, W.H.; Remark, R.; Goc, J.; Giraldo, N.A.; Becht, E.; Hammond, S.A.; Damotte, D.; Dieu-Nosjean, M.C.; Sautes-Fridman, C. The immune microenvironment: A major player in human cancers. Int. Arch. Allergy Immunol., 2014, 164 (1), 13-26.
47. Hensley-McBain, T.; Heit, A.; De Rosa, S.C.; McElrath, M.J.; Andersen-Nissen, E. Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. J. Immunol. Method., 2014, 411, 23-36
48. Ruhle, P.F.; Wunderlich, R.; Rubner, Y.; Fietkau, R.; Frey, B.; Strnad, A.; Gaipl, U.S. Longitudinal monitoring of immune status of patients with glioblastoma multiforme during radiochemotherapy. Strahlenther. Onkol., 2014, 190, 102-102.
49. Lossinsky, A.S.; Mossakowski, M.J.; Pluta, R.; Wisniewski, H.M. Intercellular adhesion molecule-1 (ICAM-1) upregulation in human brain tumors as an expression of increased blood-brain barrier permeability. Brain Pathology (Zurich, Switzerland), 1995, 5(4), 339-344.
50. Klein, R.S.; Lin, E.; Zhang, B.; Luster, A.D.; Tollett, J.; Samuel, M.A.; Engle, M.; Diamond, M.S. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J. Virol., 2005, 79(17), 11457-1166.
51. Kulprathipanja, N.V.; Kruse, C.A. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells. J. Neuroimmunol., 2004, 153(1-2), 76-82.
52. Stupp, R.; Hegi, M.E.; Mason, W.P.; Van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10(5), 459-466.
53. Qiu, B.; Zhang, D.; Wang, C.; Tao, J.; Tie, X.; Qiao, Y.; Xu, K.; Wang, Y.; Wu, A. IL-10 and TGF-beta2 are overexpressed in tumor spheres cultured from human gliomas. Mol. Biol. Report. 2011, 38(5), 3585-3591.
54. Gomez, G.G.; Kruse, C.A. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gen. Ther. Mol. Biol., 2006, 10(A), 133-146.
55. Rubner, Y.; Muth, C.; Strnad, A.; Derer, A.; Sieber, R.; Buslei, R.; Frey, B.; Fietkau, R.; Gaipl, U.S. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Rad. Oncol., 2014, 9(1), 89.
56. Fuchs, E.J.; Matzinger, P. Is cancer dangerous to the immune system? Sem.Immunology 1996, 8 (5), 271-80
57. Heil, M.; Land, W. G., Danger signals-damaged-self recognition across the tree of life. Front. Plant Sci., 2014, 5, 578.
58. Ardon, H.; Van Gool, S. W.; Verschuere, T.; Maes, W.; Fieuws, S.; Sciot, R.; Wilms, G.; Demaerel, P.; Goffin, J.; Van Calenbergh, F.; Menten, J.; Clement, P.; Debiec-Rychter, M.; De Vleeschouwer, S., Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother. Int., 2012, 61(11), 2033-2044
59. Wheeler, C.J.; Black, K.L. Vaccines for glioblastoma and high-grade glioma. Exp. Rev. Vaccin., 2011, 10(6), 875-886.
60. Polyzoidis, S.; Keyoumars, A. DCVax(R)-L-developed by Northwest Biotherapeutics. Hum. Vaccin. Immunotherapeut., 2014, e29276.
61. Van Gool, S. Immunotherapy for high-grade glioma: How to go beyond Phase I/II clinical trials. Immunotherapy, 2013, 5(10), 1043-1046.
62. Weiss, E.M.; Wunderlich, R.; Ebel, N.; Rubner, Y.; Schlucker, E.; Meyer-Pittroff, R.; Ott, O.J.; Fietkau, R.; Gaipl, U.S.; Frey, B. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front. Oncol., 2012, 2, 132.
63. Vacchelli, E.; Vitale, I.; Tartour, E.; Eggermont, A.; Sautes-Fridman, C.; Galon, J.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial watch: Anticancer radioimmunotherapy. Oncoimmunology, 2013, 2(9), e25595.
64. Frey, B.; Rubner, Y.; Kulzer, L.; Werthmoller, N.; Weiss, E.M.; Fietkau, R.; Gaipl, U.S. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol., Immunother., 2014, 63 (1), 29-36.
65. Santiago-Dieppa, D.R.; Steinberg, J.; Gonda, D.; Cheung, V.J.; Carter, B.S.; Chen, C.C. Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients. Exp. Rev. Mol. Diagnos., 2014, 14 (7), 819-825.
66. Kmiecik, J.; Poli, A.; Brons, N.H.; Waha, A.; Eide, G.E.; Enger, P. O.; Zimmer, J.; Chekenya, M. Elevated CD3+ and CD8+ tumorinfiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol., 2013, 264(1-2), 71-83.
67. Muth, C.; Schmidt, V.; Rubner, Y.; Fietkau, R.; Semrau, S.; Buslei, R.; Gaipl, U.S. Comparative analysis of the danger signals HMGB1, Hsp70, and Calreticulin in primary tumors and relapses of glioblastoma patients. Strahlenther. Onkol., 2013, 189, 124-124.
68. Schmid, T.E.; Multhoff, G. Radiation-induced stress proteins-the role of heat shock proteins (HSP) in anti-tumor responses. Curr. Med. Chem., 2012, 19(12), 1765-11770.
69. Van der Zee, J. Heating the patient: A promising approach? Ann. Oncol., 2002, 13(8), 1173-1184
70. Issels, R.D. Hyperthermia adds to chemotherapy. Euro. J. Cancer, (Oxford, England : 1990) 2008, 44 (17), 2546-2554.
71. Krawczyk, P.M.; Eppink, B.; Essers, J.; Stap, J.; Rodermond, H.; Odijk, H.; Zelensky, A.; Van Bree, C.; Stalpers, L.J.; Buist, M.R.; Soullie, T.; Rens, J.; Verhagen, H.J.; O'Connor, M.J.; Franken, N. A.; Ten Hagen, T.L.; Kanaar, R.; Aten, J.A. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc. Nat. Acad. Sci. USA, 2011, 108(24), 9851-9856.
72. Schildkopf, P.; Frey, B.; Ott, O.J.; Rubner, Y.; Multhoff, G.; Sauer, R.; Fietkau, R.; Gaipl, U.S. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother. Oncol. J. Eur. Soc. Therap. Radiol. Oncol., 2011, 101(1), 109-115.
73. Todryk, S.; Melcher, A.A.; Hardwick, N.; Linardakis, E.; Bateman, A.; Colombo, M.P.; Stoppacciaro, A.; Vile, R.G. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol., 1999, 163(3), 1398-1408
74. Multhoff, G.; Pockley, A. G.; Streffer, C.; Gaipl, U.S. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. Curr. Mol. Med., 2012, 12(9), 1174-1182.
75. Mantel, F.; Frey, B.; Haslinger, S.; Schildkopf, P.; Sieber, R.; Ott, O.J.; Lodermann, B.; Rodel, F.; Sauer, R.; Fietkau, R.; Gaipl, U.S. Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther.Onkol., 2010, 186 (11), 587-599
76. Schildkopf, P.; Frey, B.; Mantel, F.; Ott, O.J.; Weiss, E.M.; Sieber, R.; Janko, C.; Sauer, R.; Fietkau, R.; Gaipl, U. S. Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem.Biophy. Res. Commun., 2010, 391(1), 1014-1020.
77. Frey, B.; Weiss, E.M.; Rubner, Y.; Wunderlich, R.; Ott, O.J.; Sauer, R.; Fietkau, R.; Gaipl, U.S. Old and new facts about hyperthermia-induced modulations of the immune system. Int. J. Hyperthermi., 2012, 28(6), 528-542
78. Toraya-Brown, S.; Fiering, S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int. J. Hyperthermi., 2014, 30(8), 531-539.
79. Gehrmann, M.; Specht, H.M.; Bayer, C.; Brandstetter, M.; Chizzali, B.; Duma, M.; Breuninger, S.; Hube, K.; Lehnerer, S.; Van Phi, V.; Sage, E.; Schmid, T. E.; Sedelmayr, M.; Schilling, D.; Sievert, W.; Stangl, S.; Multhoff, G. Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Rad. Oncol., 2014, 9, 131.
80. Mahmoudi, K.; Hadjipanayis, C.G. The application of magnetic nanoparticles for the treatment of brain tumors. Front. Chem., 2014, 2, 109.
81. Gilchrist, R.K.; Medal, R.; Shorey, W.D.; Hanselman, R.C.; Parrott, J.C.; Taylor, C.B. Selective inductive heating of lymph nodes. Ann. Surgery, 1957, 146(4), 596-606.
82. Verma, J.; Lal, S.; Van Noorden, C.J. Nanoparticles for hyperthermic therapy: Synthesis strategies and applications in glioblastoma. Int. J. Nanomed., 2014, 9, 2863-2877.
83. Ito, A.; Honda, H.; Kobayashi, T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: A novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol. Immunother., 2006, 55(3), 320-328.
84. Yi, G.Q.; Gu, B.; Chen, L.K. The safety and efficacy of magnetic nano-iron hyperthermia therapy on rat brain glioma. Tumour Biol., 2014, 35(3), 2445-2449.
85. Curtin, J.F.; Liu, N.; Candolfi, M.; Xiong, W.; Assi, H.; Yagiz, K.; Edwards, M.R.; Michelsen, K.S.; Kroeger, K.M.; Liu, C.; Muhammad, A.K.; Clark, M.C.; Arditi, M.; Comin-Anduix, B.; Ribas, A.; Lowenstein, P.R.; Castro, M.G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med., 2009, 6 (1), e10.
86. Balachandran, V.P.; Cavnar, M.J.; Zeng, S.; Bamboat, Z.M.; Ocuin, L.M.; Obaid, H.; Sorenson, E.C.; Popow, R.; Ariyan, C.; Rossi, F.; Besmer, P.; Guo, T.; Antonescu, C.R.; Taguchi, T.; Yuan, J.; Wolchok, J.D.; Allison, J.P.; DeMatteo, R.P. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med., 2011, 17(9), 1094-100
87. Koblish, H. K.; Hansbury, M.J.; Bowman, K.J.; Yang, G.; Neilan, C.L.; Haley, P.J.; Burn, T.C.; Waeltz, P.; Sparks, R.B.; Yue, E.W.; Combs, A. P.; Scherle, P.A.; Vaddi, K.; Fridman, J.S. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Therapeu., 2010, 9(2), 489-498
88. Srivastava, M.K.; Zhu, L.; Harris-White, M.; Kar, U.K.; Huang, M.; Johnson, M.F.; Lee, J.M.; Elashoff, D.; Strieter, R.; Dubinett, S.; Sharma, S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS one, 2012, 7(7), e40677.